Latest FDA News | Page 7

Restoring Lost Sense of Smell
Pharmaxis reports positive analysis of data from phase 2 PXS-5505 study
Lumos completes placement and launches share purchase plan
Moderna submits RSV vaccine to global regulatory agencies
Solar Powered Sunscreen: EcoZinc a World First in Sustainable Zinc Oxide Innovation
Neuren opens first site in US for Prader-Willi syndrome Phase 2 trial
Vague language impacts perceptions of vaping risks, study finds
We are closer than ever to being able to 3D print medicines. Here’s why that’s important
AVITA Medical announces FDA approval of RECELL for skin repigmentation in vitiligo patients
Capivasertib in combination with Faslodex granted Priority Review in the US for patients with advanced HR-positive breast cancer
Nirsevimab unanimously recommended by FDA Advisory Committee for the prevention of RSV lower respiratory tract disease in infants
Neuren Pharmaceuticals receives milestone payment from US partner
Kinoxis awarded new US grant funding to support clinical development of KNX100 for opioid use disorder
Aravax launches new Phase 2 trial of peanut allergy candidate
Optiscan Imaging launches entitlement offer to raise $16.7 million
Q-Gen Cell Therapeutics leading the charge in revolutionary cell therapy research
Energy Breakthrough gets waste wise
The FDA finally approved Elon Musk’s Neuralink chip for human trials. Have all the concerns been addressed?
SCEMBLIX®, A NOVEL TREATMENT, NOW LISTED ON THE PBS FOR ADULT PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
E-cigarette companies seek IP protections in face of rising regulation
Chimeric Therapeutics announces new capital raise
‘We Are So Sick as a Nation’: Food is Medicine Summit Puts Focus on Nutrition
We worked out how many tobacco lobbyists end up in government, and vice versa. It’s a lot
FDA removes clinical hold on Immuron’s new campylobacter ETEC therapeutic
Update on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer
The Future Is Now: Wrestling with Ethics, Policy and Brain-Computer Interfaces
Collaborative and creative policies needed to maximize psychedelics’ therapeutic potential
Major milestone for Australian pharmaceutical company, Neuren
Microsoft and Epic expand strategic collaboration with integration of Azure OpenAI Service
Cynata receives ethics approval for proposed aGvHD Phase 2 clinical trial
Pharmaxis adds combination arm to PXS‐5505 myelofibrosis study
American Gastroenterological Association invests in unsedated transnasal endoscopy medical device company, EvoEndo®
TGA review strengthens case for much tighter vape restrictions at the border
We’ve been connecting brains to computers longer than you’d expect. These 3 companies are leading the way
Chimeric Therapeutics reports ‘positive feedback’ on plan for CHM 2101
$7.5 million in grants for medical research
Interim analysis shows accuracy of Optiscan Imaging platform
FDA grants ‘orphan’ designation to PTX-100 for broader TCL indications
Update on US regulatory review of Lynparza in combination with abiraterone for metastatic castration-resistant prostate cancer
Update on effectiveness of monoclonal antibodies against COVID variants
Is there a vaccine for RSV or respiratory syncytial virus? After almost 60 years, several come at once
Weill Cornell Medicine grants to advance lymphoma research
Inhalable ‘SHIELD’ Protects Lungs Against Covid, Flu Viruses
Where did all diabetes drugs go?
AusBiotech advocates for sustainable funding model for TGA
Export success icing on cake for Dollar Sweets
FDA approves IND for Prader-Willi syndrome study of Neuren’s NNZ-2591
Dimerix confirms the outcomes of a meeting with the FDA on paediatric plan for DMX-200